A service of the U.S. National Library of Medicine
National Institutes of Health
Could Stem Cells Cure Drug-Resistant Tuberculosis?
Small, early study found treatment was safe, possibly more effective than standard antibioticsThursday, January 9, 2014
THURSDAY, Jan. 9, 2014 (HealthDay News) -- A patient's own bone marrow stem cells might someday be used to treat multidrug-resistant tuberculosis, a new study suggests.
The phase 1 study to assess the safety of the treatment included 30 patients, aged 21 to 65, with multidrug-resistant tuberculosis or the even more dangerous extensively drug-resistant tuberculosis. They received standard tuberculosis antibiotic treatment and an infusion of about 10 million of their own bone marrow stem cells.
A comparison group of 30 patients with either type of tuberculosis received standard treatment only.
After 18 months, 16 patients treated with bone marrow stem cells were cured, compared with five patients in the standard group, the study authors said. The most common side effects in the stem cell group were high cholesterol (14 patients), nausea (11), and lymphopenia (low white blood cell count) or diarrhea (10).
There were no serious side effects, according to the study, which was published Jan. 8 in The Lancet Respiratory Medicine.
Conventional treatment for multidrug-resistant tuberculosis uses a combination of antibiotics that can cause harmful side effects in patients, study leader Markus Maeurer, a professor at Karolinska University Hospital in Sweden, said in a journal news release.
"Our new approach, using the patients' own bone marrow stromal cells, is safe and could help overcome the body's excessive inflammatory response, repair and regenerate inflammation-induced damage to lung tissue, and lead to improved cure rates," Maeurer said in the news release.
Longer follow-up with more patients is needed to confirm the safety and effectiveness of the stem cell therapy, he said.
About 450,000 people in Eastern Europe, Asia and South Africa have multidrug-resistant tuberculosis, and about half of them will not respond to existing treatments, according to the World Health Organization.
SOURCE: The Lancet Respiratory Medicine, news release, Jan. 8, 2014
Copyright (c) 2014 HealthDay. All rights reserved.